Elevated absolute eosinophil counts and absolute basophil counts (ABC) are associated with reduced overall survival in essential thrombocythemia. In polycythemia vera, higher ABC correlates with ...

71% (12/17) showed a decrease in Total Symptom Score (TSS). 53% (9/17) showed a ≥50% decrease in TSS. Patients with all genotypes identified in the study (CALR, JAK2 V617F, Triple Negative) responded ...

To the authors’ knowledge, the study is the first to include a patient with essential thrombocythemia (ET) and MPL and Type 1 calreticulin gene mutations. Authors of a case study suggest screening for ...

Rami Komrokji, M.D.: Once we establish a diagnosis, our next step is thinking of the risk of a disease, because as you mentioned, those diseases are serious, but the risks vary. Maybe you can tell us ...

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep ...

Over the past 35 years, interferons have been explored in various formulations for the management of Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs), such as essential ...

The Shorespan-007 trial will investigate the new drug among patients with essential thrombocythemia who have not previously received cytoreductive therapy. A second phase 3 clinical trial has been ...

If you have the JAK2 V617F mutation, are aged 18-74 years old, do not smoke, do not have any known autoimmune disease, and attend medical checks at UAB regularly, you may be eligible for our study!

An open-label, multicenter, expanded access study assessing the safety and efficacy of oral ruxolitinib administered to patients with primary myelofibrosis (PMF), post-polycythemia myelofibrosis (PPV ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Dear Dr. Roach • Recently, I was diagnosed with essential thrombocythemia. The recommended treatment is the drug hydroxyurea ...